Clinical Chemistry Email Content Delivery
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 46: 1521-1522, 2000;
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ash, J.
Right arrow Articles by Kadijevic, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ash, J.
Right arrow Articles by Kadijevic, L.
(Clinical Chemistry. 2000;46:1521-1522.)
© 2000 American Association for Clinical Chemistry, Inc.

Abstracts of Oak Ridge Posters

Development of an Automated Quantitative Latex Immunoassay for Cardiac Troponin I in Serum,

Judy Asha, George Baxevanakis1, Lela Bilandzic1, Howard Shin1 and Lilly Kadijevic1

1 Spectral Diagnostics Inc., 135-2 The West Mall, Toronto, Ontario, M9C1C2 Canada
a author for correspondence: fax 416-626-3651, e-mail jash@spectraldiagnostics.com

Currently, the measurement of troponin I (TnI) can only be accomplished through the use of heterogeneous assays on closed-system automated analyzers. The development of this new and innovative latex technology will allow the measurement of TnI on a variety of turbidimetry-based open-system instruments, greatly enhancing clinical applicability of this test.

Determining the presence of TnI in the serum of patients is an important aid in the diagnosis of myocardial infarction. An advantage of TnI is its improved specificity for myocardial damage compared with creatine kinase-MB (1). In addition, there is strong evidence that future utilization of TnI will be for risk stratification to assist in the decision process for therapeutic intervention with glycoprotein II/IIIa inhibitors or low-molecular weight heparin (2)(3). In fact, the GUSTO trial, which should be completed soon, included TnI as one of the cardiac markers to be considered for risk stratification. The cardiac troponin complex is part of the contractile apparatus of the thin filament in striated muscle and consists of subunits C, T, and I. Different isoforms of TnI exist in the skeletal and cardiac muscles (fast skeletal, slow skeletal, and cardiac TnI). The distinct structural heterogeneity between these isoforms allows production of specific antibodies (4), which can be utilized by the latex assay to detect serum TnI in clinical conditions . . . [Full Text of this Article]


References






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2000 by the American Association for Clinical Chemistry.